BiotechTube

Lorcaserin

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity, Weight Loss, Overweight

Trial Timeline

Apr 11, 2017 → Apr 11, 2019

NCT ID
NCT03552107

About Lorcaserin

Lorcaserin is a pre-clinical stage product being developed by Eisai for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT03552107. Target conditions include Obesity, Weight Loss, Overweight.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04457687Pre-clinicalActive
NCT03552107Pre-clinicalCompleted
NCT02022956Phase 1Completed
NCT00828581Phase 1Completed
NCT00828932Phase 1Completed

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
Eloralintide + PlaceboEli LillyPhase 1
29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
27
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43